Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00533520
Recruitment Status : Completed
First Posted : September 21, 2007
Last Update Posted : November 25, 2013
Genentech, Inc.
Information provided by (Responsible Party):
Brandon G. Busbee, MD, Tennessee Retina

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2013
  Actual Study Completion Date : November 2013